Improving the evaluation of new cancer treatments: Challenges and opportunities

Mace L. Rothenberg; David P. Carbone; David H. Johnson

doi:10.1038/nrc1047

Improving the evaluation of new cancer treatments: Challenges and opportunities

Mace L. Rothenberg, David P. Carbone, David H. Johnson

Research output: Contribution to journal › Review article › peer-review

132 Scopus citations

Abstract

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

Original language	English (US)
Pages (from-to)	303-309
Number of pages	7
Journal	Nature Reviews Cancer
Volume	3
Issue number	4
DOIs	https://doi.org/10.1038/nrc1047
State	Published - Apr 2003

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/nrc1047

Cite this

@article{1628d6d9195243efbf537c6fa2b1fdaa,

title = "Improving the evaluation of new cancer treatments: Challenges and opportunities",

abstract = "There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?",

author = "Rothenberg, {Mace L.} and Carbone, {David P.} and Johnson, {David H.}",

note = "Funding Information: Supported, in part, by National Institutes of Health grants and the Ingram Charitable Trust.",

year = "2003",

month = apr,

doi = "10.1038/nrc1047",

language = "English (US)",

volume = "3",

pages = "303--309",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Improving the evaluation of new cancer treatments

T2 - Challenges and opportunities

AU - Rothenberg, Mace L.

AU - Carbone, David P.

AU - Johnson, David H.

N1 - Funding Information: Supported, in part, by National Institutes of Health grants and the Ingram Charitable Trust.

PY - 2003/4

Y1 - 2003/4

N2 - There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

AB - There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

UR - http://www.scopus.com/inward/record.url?scp=0037899935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037899935&partnerID=8YFLogxK

U2 - 10.1038/nrc1047

DO - 10.1038/nrc1047

M3 - Review article

C2 - 12671669

AN - SCOPUS:0037899935

SN - 1474-175X

VL - 3

SP - 303

EP - 309

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

IS - 4

ER -

Improving the evaluation of new cancer treatments: Challenges and opportunities

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this